Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing sugar and lipid reducing medicine and aspirin and folic acid

A technology of lowering blood sugar and lipids, aspirin, applied in the field of medicine, can solve problems such as ignoring early intervention of diabetic complications

Inactive Publication Date: 2017-01-11
SHENZHEN AUSA PHARM CO LTD +2
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Most of the anti-diabetic drugs currently on the market focus on correcting the abnormal state of blood sugar and metabolic disorders of diabetes, while ignoring the early intervention of the composite risk factors that lead to diabetic complications (such as diabetic vascular disease) to a certain extent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing sugar and lipid reducing medicine and aspirin and folic acid
  • Pharmaceutical composition containing sugar and lipid reducing medicine and aspirin and folic acid
  • Pharmaceutical composition containing sugar and lipid reducing medicine and aspirin and folic acid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 Preparation of Compound Glimepiride / Rosuvastatin / Aspirin / Folic Acid Tablets (1000 Tablets)

[0052] formula:

[0053]

[0054] Preparation:

[0055] The raw and auxiliary materials are crushed through an 80-mesh sieve, and dried for later use. Take the prescribed amount of glimepiride, rosuvastatin, aspirin, and folic acid and mix them evenly according to the method of equal increments. Mix to get powder A, set aside. Dibasic calcium phosphate and lactose were passed through a 100-mesh sieve and dried at 75°C for 2 hours. Mix powder A with the mixed calcium hydrogen phosphate and lactose in equal increments. Add appropriate amount of povidone K30 aqueous solution binder to make soft material, granulate with 20-mesh sieve, dry at 40-45°C; dry granules are granulated with 20-mesh sieve. Add 1% magnesium stearate to the dry granules and put them into a V-shaped mixer to mix evenly. Determination of particle content and loss on drying. Calculate the tab...

Embodiment 2～17

[0056] Examples 2-17 : the preparation of the compound tablet of different content proportioning (1000 pieces quantity)

[0057] The preparation method of Examples 2-17 is the same as that of Example 1, and the granules obtained according to the formula shown in Table 1 are made into tablets.

[0058] Table 1 Example 2~9 Tablet Formulation Composition

[0059]

[0060] Continuation of Table 1 Embodiment 10~17 tablet formula composition

[0061]

[0062]

Embodiment 18

[0063] Example 18 Preparation of sitagliptin / simvastatin / aspirin / folic acid capsules (1000 capsules)

[0064] formula:

[0065]

[0066] Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 50g of sitagliptin, 30g of simvastatin, 75g of aspirin, and 0.8g of folic acid and mix them uniformly according to the method of equal increase, and add calcium hydrogen phosphate, lactose, sodium carboxymethyl starch and low-substituted hydroxypropyl cellulose respectively, and follow the method of etc. Mix evenly with the method of increasing quantity, make soft material with povidone ethanol solution, granulate with 20 mesh sieve, dry at 40°C for about 2 hours, granulate with 18 mesh sieve, control the water content of the granules to 2-3%, and dry the dried Granules and micropowder silica gel are evenly mixed, the semi-finished product is tested, the content is measured, and it is filled into hollow capsules. Pay attentio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a quadruple pharmaceutical composition containing a sugar reducing medicine, a lipid reducing medicine and aspirin and folic acid, wherein the sugar reducing medicine is one of biguanide, sulfonylurea, thiazolidinedione, alpha-glycoside inhibitor or dipeptidyl peptidase IV (DPP-4) inhibitor medicines; the lipid reducing medicine is one of statins (3-hydroxymethyl glutaryl coenzyme A reductase inhibitor); and the aspirin content is preferably 50-150mg while the folic acid content is preferably 0.4-1.2mg. The invention also relates to an application of the quadruple composition in preparing a diabetes treatment medicine. A medicine prepared from the pharmaceutical composition provided by the invention has the beneficial effects of regulating blood lipid and preventing or relieving vascular complications of diabetes on the basis of effectively reducing blood sugar, and thus is a more suitable anti-diabetic medicine.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing hypoglycemic drugs, lipid-lowering drugs, aspirin and folic acid, which is used for treating diabetes and associated blood lipid disorders and preventing diabetic vascular complications. The invention belongs to the field of medicine. Background technique [0002] Diabetes mellitus is a common endocrine and metabolic disease characterized by chronic hyperglycemia accompanied by disturbances in sugar, fat and protein metabolism caused by insufficient insulin secretion and / or action defects. According to epidemiological surveys, the prevalence of diabetes in my country is as high as 9.7%, and it is estimated that the total number of adult diabetic patients in the country is 92.4 million [Yang W, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090-1101], type 2 diabetes mellitus (T2DM) accounts for more than 90%. In addition, according to the statistics...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/616A61K31/519A61K31/64A61K31/505A61K31/7036A61P3/10A61P3/06A61P7/02A61P9/10A61P13/12A61K31/366A61K31/4439A61K31/155A61K31/40
CPCA61K45/06A61K31/155A61K31/366A61K31/40A61K31/4439A61K31/505A61K31/519A61K31/616A61K31/64A61K31/7036A61K2300/00
Inventor 段洪伟张磊徐希平于多白洁
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com